CNSP Logo

CNS Pharmaceuticals, Inc. (CNSP) 

NASDAQ
Market Cap
$436,152.00
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
254 of 809
Rank in Industry
150 of 445

Largest Insider Buys in Sector

CNSP Stock Price History Chart

CNSP Stock Performance

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Insider Activity of CNS Pharmaceuticals, Inc.

Over the last 12 months, insiders at CNS Pharmaceuticals, Inc. have bought $129,121 and sold $0 worth of CNS Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at CNS Pharmaceuticals, Inc. have bought $114,645 and sold $133,114 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Downs Christopher (Chief Financial Officer) — $108,353. Climaco John M (Chief Executive Officer) — $54,944. Evans Carl Anthony (director) — $10,000.

The last purchase of 166,666 shares for transaction amount of $50,000 was made by Climaco John M (Chief Executive Officer) on 2024‑02‑01.

List of Insider Buy and Sell Transactions, CNS Pharmaceuticals, Inc.

2024-02-01PurchaseClimaco John MChief Executive Officer
166,666
3.2195%
$0.30$50,000-9.34%
2024-02-01PurchaseDowns ChristopherChief Financial Officer
66,666
1.2878%
$0.30$20,000-9.34%
2024-02-01PurchaseGumulka Jerzydirector
33,333
0.6439%
$0.30$10,000-9.34%
2024-02-01PurchaseEvans Carl Anthonydirector
33,333
0.6439%
$0.30$10,000-9.34%
2023-08-22PurchaseDowns ChristopherChief Financial Officer
27,000
0.4674%
$1.27$34,177-67.70%
2023-08-16PurchaseClimaco John MChief Executive Officer
2,750
0.0656%
$1.80$4,945-65.10%
2023-04-19PurchaseGumulka Jerzydirector
2,500
0.1259%
$1.70$4,250-10.45%
2023-04-17PurchaseDowns ChristopherChief Financial Officer
3,100
0.1892%
$3.20$9,920-42.00%
2023-04-12PurchaseClimaco John MChief Executive Officer
15,000
0.8017%
$0.69$10,409+137.15%
2023-04-10PurchaseGumulka Jerzydirector
7,173
0.3716%
$0.74$5,308+115.56%
2023-03-28SalePriebe Waldemar10 percent owner
10,000
0.551%
$1.04$10,400+63.13%
2023-03-27SalePriebe Waldemar10 percent owner
5,000
0.2623%
$1.09$5,450+48.17%
2023-03-24SalePriebe Waldemar10 percent owner
5,000
0.2485%
$1.08$5,400+42.11%
2023-03-23SalePriebe Waldemar10 percent owner
10,000
0.5395%
$1.08$10,800+54.29%
2023-03-22SalePriebe Waldemar10 percent owner
5,000
0.2552%
$1.08$5,400+45.50%
2023-03-21SalePriebe Waldemar10 percent owner
5,000
0.2623%
$1.10$5,500+46.82%
2023-03-20SalePriebe Waldemar10 percent owner
5,000
0.2599%
$1.08$5,400+48.17%
2023-03-17SalePriebe Waldemar10 percent owner
5,000
0.2646%
$1.13$5,650+44.64%
2023-03-16SalePriebe Waldemar10 percent owner
5,000
0.2756%
$1.24$6,200+37.29%
2023-03-15SalePriebe Waldemar10 percent owner
5,000
0.258%
$1.22$6,100+30.24%

Insider Historical Profitability

50.07%
Climaco John MChief Executive Officer
215676
2.5584%
$1.8430+137.15%
Downs ChristopherChief Financial Officer
103438
1.227%
$1.8460<0.0001%
Gumulka Jerzydirector
43006
0.5101%
$1.8430+52.56%
Evans Carl Anthonydirector
33458
0.3969%
$1.8410
Priebe Waldemar10 percent owner
156807
1.86%
$1.84017

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
No records found…